3rd Obesity & Weight Loss Drug Development Summit West

Optimizing Tolerability, Quality of Weight Loss & Personalized Therapies to Drive Competitive Drug Development

As obesity drug development enters a defining new chapter, the race is no longer about developing the next GLP-1, but delivering the next breakthrough in tolerability, muscle preservation, patient adherence, precision medicine, and long-term outcomes. With hundreds of obesity assets in development and billions of dollars invested in the space, 2026 is a pivotal moment for companies to differentiate their pipelines, benchmark their strategies, and secure their position in the market.

The 3rd Obesity & Weight Loss Drug Development Summit West is where the industry’s most innovative pharma and biotech leaders come together to answer the questions that will shape the next decade of obesity therapeutics. While many events focus on clinical readouts or broad discussions around obesity care, this summit is dedicated to the practical challenges and strategic decisions driving drug development success.

Bringing together 80+ senior executives, and decision-makers, this intimate, industry-focused forum offers unparalleled opportunities to exchange insights, build meaningful partnerships, and understand what today’s innovation really means for tomorrow’s therapies. If you’re serious about advancing next-generation obesity therapeutics, this is the room you need to be in.

To know more visit: https://ter.li/hexuee5e